Catalysts for $AMGN

AMGEN INC earnings

AMGEN INC earnings

BKEMV (ECULIZUMAB-AEEB) — FDA approval

ENBREL (ETANERCEPT) — FDA approval

OTEZLA (APREMILAST) — FDA approval

ENBREL (ETANERCEPT) — FDA approval

BKEMV (ECULIZUMAB-AEEB) — FDA approval

IMDELLTRA (TARLATAMAB-DLLE) — FDA approval

BLINCYTO (BLINATUMOMAB) — FDA approval

AMJEVITA (ADALIMUMAB-ATTO) — FDA approval

WEZLANA (USTEKINUMAB-AUUB) — FDA approval

WEZLANA (USTEKINUMAB-AUUB) — FDA approval

AMJEVITA (ADALIMUMAB-ATTO) — FDA approval

BKEMV (ECULIZUMAB-AEEB) — FDA approval

Mckesson Medical-Surgical Inc. Corporate Office recall (Cls II)

Mckesson Medical-Surgical Inc. Corporate Office recall (Cls II)

OTEZLA (APREMILAST) — FDA approval

ENBREL (ETANERCEPT) — FDA approval

AMJEVITA (ADALIMUMAB-ATTO) — FDA approval

BLINCYTO (BLINATUMOMAB) — FDA approval

BKEMV (ECULIZUMAB-AEEB) — FDA approval

AMJEVITA (ADALIMUMAB-ATTO) — FDA approval

Amgen, Inc. recall (Cls II)

Amgen, Inc. recall (Cls II)

BKEMV (ECULIZUMAB-AEEB) — FDA approval

WEZLANA (USTEKINUMAB-AUUB) — FDA approval

WEZLANA (USTEKINUMAB-AUUB) — FDA approval

BLINCYTO (BLINATUMOMAB) — FDA approval

BKEMV (ECULIZUMAB-AEEB) — FDA approval

ENBREL (ETANERCEPT) — FDA approval